Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1217-1223

  Byakika Kibwika, Pauline ^a,b,c   Lamorde, Mohammed ^a,b   Okaba Kayom, Violet ^a   Mayanja Kizza, Harriet ^a,c   Katabira, Elly ^a,c   Hanpithakpong, Warunee ^d   Pakker, Nadine ^c   Dorlo, Thomas P C ^e,f   Tarning, Joel ^d,g   Lindegardh, Niklas ^d,g   de vries, Peter J ^f   Back, David ^h   Khoo, Saye ^h   Merry, Concepta ^a,b,c  

^a MAKERERE UNIVERSITY   (Uganda)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c Infectious Diseases Network for Treatment and Research in Africa   (Uganda)

^d MAHIDOL UNIVERSITY   (Thailand)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antimalarials; Antiretrovirals; Drug interactions

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; COTRIMOXAZOLE; DIDANOSINE; DIHYDROARTEMISININ; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART FUNCTION TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIMALARIALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALARIA; MALE; UGANDA;

EID: 84859609445     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr596     Document Type: Article

References (43)

1. UNAIDS and WHO. 09 AIDS Epidemic Update. http://data.unaids.org/pub/report/2009/jc1700_epi_update_2009_en.pdf (14 November 2011, date last accessed).
2. WHO. Guidelines for the Treatment of Malaria. Geneva: WHO, 2010.
3. Whitworth J, Morgan D, Quigley M et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356: 1051-6.
4. French N, Nakiyingi J, Lugada E et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15: 899-906.
5. Kublin JG, Patnaik P, Jere CS et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365: 233-40.
6. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314: 1603-6.
7. UNAIDS and WHO. UNAIDS Report on the Global AIDS Epidemic. 2010. http://www.unaids.org/documents/20101123_GlobalReport_em.pdf (14 November 2011, date last accessed).
8. Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS 2005; 19: 995-1005.
9. Barry M, Mulcahy F, Merry C et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304.
10. Novartis Pharmaceuticals Corporation. Coartem (Artemether and Lumefantrine) Tablet: Human Prescription Drug Label. http://www.pharma.us.novartis.com/product/pi/pdf/coartem.pdf (9 August 2011 2011, date last accessed).
11. Kokwaro G, Mwai L, Nzila A. Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria. Expert Opin Pharmacother 2007; 8: 75-94.
12. German PI, Aweeka FT. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2008; 47: 91-102.
13. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+ benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46: 553-61.
14. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet 1999; 37: 105-25.
15. White N. Preventing antimalarial drug resistance through combinations. Drug Resist Updat 1998; 1: 3-9.
16. Djimdé A, Lefèvre G. Understanding the pharmacokinetics of Coartem. Malar J 2009; 8 Suppl 1: S4.
17. Malvy D, Receveur MC, Ozon P et al. Fatal cardiac incident after use of halofantrine. J Trav Med 2000; 7: 215-6.
18. Touze JE, Bernard J, Keundjian A et al. Electrocardiographic changes and halofantrine plasma level during acute falciparum malaria. American J Trop Med Hyg 1996; 54: 225-8.
19. Giudicelli CP, Touze JE, Bernard J. [Electrocardiographic changes due to halofantrine in the treatment of malaria: therapeutic implications]. Bull Acad Natl Med 1996; 180: 71-80; discussion 80-2.
20. German P, Parikh S, Lawrence J et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424-9.
21. Ashley EA, Stepniewska K, Lindegårdh N et al. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health 2007; 12: 195-200.
22. Hanpithakpong W, Kamanikom B, Dondorp AM et al. A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 876: 61-8.
23. Annerberg A, Singtoroj T, Tipmanee P et al. High throughput assay for the determination of lumefantrine in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 822: 330-3.
24. Byakika-Kibwika P, Lamorde M, Lwabi P et al. Cardiac conduction safety during coadministration of artemether-lumefantrine and lopinavir/ritonavir in HIV-infected Ugandan adults. Chemother Res Practice 2011; doi:10.1155/2011/393976.
25. Lubomirov R, di Iulio J, Fayet A et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 2010; 20: 217-30.
26. Haas DW, Ribaudo HJ, Kim RB et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
27. Piedade R, Gil JP. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin Drug Metab Toxicol 2011; 7: 1185-200.
28. van Agtmael MA, Cheng-Qi S, Qing JX et al. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 1999; 12: 151-8.
29. Wyen C, Fuhr U, Frank D et al. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther 2008; 84: 75-82.
30. Yeh RF, Gaver VE, Patterson KB et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42: 52-60.
31. Corbett AH, Lim ML, Kashuba AD. Kaletra (lopinavir/ritonavir). Ann Pharmacother 2002; 36: 1193-203.
32. Cooper CL, van Heeswijk RP, Gallicano K et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003; 36: 1585-92.
33. Weemhoff JL, von Moltke LL, Richert C et al. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol 2003; 55: 381-6.
34. Lefèvre G, Carpenter P, Souppart C et al. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol 2002; 54: 485-92.
35. van Agtmael M, Gupta V, van der Wösten TH et al. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol 1999; 55: 405-10.
36. Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-59.
37. Faucette SR, Zhang TC, Moore R et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007; 320: 72-80.
38. Xie W, Yeuh MF, Radominska-Pandya A et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad SciUSA2003;100: 4150-5.
39. Zhang D, Chando TJ, Everett DW et al. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729-39.
40. Price RN, Uhlemann AC, van Vugt M et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 2006; 42: 1570-7.
41. Van Geertruyden JP, Menten J, Colebunders R et al. The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance. Malar J 2008; 7: 134.
42. Ittarrat W, Pickard AL, Rattanasinganchan P et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors.AmJ TropMed Hyg 2003; 68: 147-52.
43. Ezzet F, van Vugt M, Nosten F et al. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44: 697-704.